A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
2019
2019
Historique:
received:
14
10
2018
accepted:
17
01
2019
entrez:
19
2
2019
pubmed:
19
2
2019
medline:
19
2
2019
Statut:
epublish
Résumé
The World Health Organization has identified Lassa virus (LASV) as one of the top five pathogens to cause a severe outbreak in the near future. This study assesses the ability of a leading vaccine candidate, recombinant Vesicular stomatitis virus expressing LASV glycoprotein (VSVΔG/LASVGPC), and its ability to induce rapid and long-term immunity to lethal guinea pig-adapted LASV (GPA-LASV). Outbred guinea pigs were vaccinated with a single dose of VSVΔG/LASVGPC followed by a lethal challenge of GPA-LASV at 7, 14, 25, 189, and 355 days post-vaccination. Statistically significant rapid and long-term protection was achieved at all time points with 100% protection at days 7 and 14 post-vaccination. While 83 and 87% protection were achieved at 25 days and 6 months post-vaccination, respectively. When guinea pigs were challenged one year after vaccination 71% protection was achieved. Notable infectious virus was isolated from the serum and tissues of some but not all animals. Total LASVGPC-specific IgG titers were also measured on a monthly basis leading up to LASV challenge however, it is unclear if antibody alone correlates with short and long term survival. These studies confirm that a single dose of VSVΔG/LASVGPC can induce rapid and long-term protection from LASV infection in an aggressive outbred model of infection, and supports further development in non-human primates.
Identifiants
pubmed: 30774999
doi: 10.1038/s41541-019-0104-x
pii: 104
pmc: PMC6368541
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
J Virol. 2001 Dec;75(23):11677-85
pubmed: 11689649
Vector Borne Zoonotic Dis. 2001 Winter;1(4):269-81
pubmed: 12653127
J Virol. 2004 May;78(10):5458-65
pubmed: 15113924
PLoS Med. 2005 Jun;2(6):e183
pubmed: 15971954
J Med Virol. 1992 May;37(1):1-7
pubmed: 1619397
J Vector Borne Dis. 2007 Mar;44(1):1-11
pubmed: 17378212
Antiviral Res. 2008 Apr;78(1):79-90
pubmed: 18036672
Vaccine. 2008 Sep 26;26(41):5246-54
pubmed: 18692539
Vopr Virusol. 1991 Mar-Apr;36(2):146-50
pubmed: 1882522
J Virol. 2011 Dec;85(23):12781-91
pubmed: 21917979
PLoS One. 2014 Apr 23;9(4):e94355
pubmed: 24759889
Vaccine. 2014 Sep 29;32(43):5722-9
pubmed: 25173474
PLoS Negl Trop Dis. 2015 Apr 17;9(4):e0003736
pubmed: 25884628
Lancet. 2015 Aug 29;386(9996):857-66
pubmed: 26248676
Vaccines (Basel). 2013 Jul 18;1(3):262-77
pubmed: 26344112
Sci Rep. 2015 Oct 12;5:14775
pubmed: 26456301
World J Virol. 2016 May 12;5(2):85-6
pubmed: 27175354
Rev Infect Dis. 1989 May-Jun;11 Suppl 4:S783-9
pubmed: 2749109
Antiviral Res. 2016 Sep;133:218-222
pubmed: 27531367
Nat Med. 2017 Oct;23(10):1146-1149
pubmed: 28869611
Hum Vaccin Immunother. 2017 Dec 2;13(12):3010-3019
pubmed: 29135337
Vaccine. 2018 Jan 29;36(5):683-690
pubmed: 29287681
Drug Des Devel Ther. 2018 Aug 14;12:2519-2527
pubmed: 30147299
Nat Commun. 2018 Oct 11;9(1):4223
pubmed: 30310067
J Infect Dis. 1987 Mar;155(3):445-55
pubmed: 3805772
Science. 1974 Jul 19;185(4147):263-5
pubmed: 4833828
BMJ. 1995 Sep 30;311(7009):857-9
pubmed: 7580496